Chun T W, Fauci A S
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10958-61. doi: 10.1073/pnas.96.20.10958.
The use of highly active antiretroviral therapy (HAART) in the treatment of HIV-1-infected individuals has provided a considerable amount of information regarding the dynamics of viral replication and has resulted in enormous advances in HIV therapeutics. The profound suppression of plasma viremia in HIV-infected individuals receiving HAART has resulted in a highly beneficial clinical effect and a dramatic decrease in the death rate attributable to AIDS. Nonetheless, the persistance of reservoirs of HIV, including latently infected, resting CD4+ T cells that can give rise to infectious HIV upon stimulation in vitro, has posed a sobering challenge to the long-term control or eradication of HIV in infected individuals receiving HAART. Although a recent study has demonstrated th at the size of the pool of latently infected, resting CD4+ T cells can be markedly diminished with intermittent interleukin (IL-2) and continuous HAART, complete eradication of HiV in infected individuals remains extremely problematic. Here we discuss recent developments in studies of the latent reservoir of HIV in patients receiving HAART and implications for the long-term treatment of infected individuals and eradication of the infection.
使用高效抗逆转录病毒疗法(HAART)治疗HIV-1感染者,已提供了大量有关病毒复制动态的信息,并在HIV治疗方面取得了巨大进展。接受HAART治疗的HIV感染者血浆病毒血症受到深度抑制,产生了非常有益的临床效果,并显著降低了艾滋病所致死亡率。尽管如此,HIV储存库持续存在,包括潜伏感染的静息CD4+T细胞,这些细胞在体外受到刺激时可产生具有传染性的HIV,这对接受HAART治疗的感染者长期控制或根除HIV构成了严峻挑战。虽然最近一项研究表明,间歇性白细胞介素(IL-2)和持续HAART可使潜伏感染的静息CD4+T细胞池大小显著减少,但在感染者中完全根除HIV仍然极具问题。在此,我们讨论接受HAART治疗患者中HIV潜伏储存库研究的最新进展,以及对感染者长期治疗和根除感染的意义。